Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Enanta Pharmaceuticals Inc ENTA

Healthcare Biotechnology
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered... see more

Recent & Breaking News (NDAQ:ENTA)

Enanta Pharmaceuticals Announces Submission of EU Marketing Authorization Applications to the European Medicines Agency for All-Oral, Interferon-Free Hepatitis C Regimen Containing ABT-450

Business Wire May 8, 2014

AbbVie Submits for EU Marketing Authorization its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Chronic Hepatitis C

PR Newswire May 8, 2014

Enanta Pharmaceuticals to Present at the 39th Annual Deutsche Bank Securities Healthcare Conference

Business Wire April 30, 2014

Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Second Quarter and Six Months Ended March 31, 2014

Business Wire April 28, 2014

Enanta Pharmaceuticals Announces New Drug Application Submission to the U.S. FDA for All-Oral, Interferon-Free Hepatitis C Regimen

Business Wire April 22, 2014

AbbVie Submits New Drug Application to U.S. FDA for its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C

PR Newswire April 22, 2014

Enanta Pharmaceuticals Announces Detailed Data from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis being Presented at the European Association for the Study of the Liver (EASL) Meeting

Business Wire April 12, 2014

AbbVie to Present Late-Breaking Results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis at the 2014 International Liver Congress(TM)

PR Newswire April 12, 2014

Enanta Pharmaceuticals Announces Detailed Data from SAPPHIRE-I and SAPPHIRE-II Phase 3 Studies in Patients with Chronic Hepatitis C Virus Being Presented at the European Association for the Study of the Liver (EASL) Meeting

Business Wire April 11, 2014

AbbVie to Present Detailed Phase III Results from SAPPHIRE-I and SAPPHIRE-II Studies in Chronic Hepatitis C Patients at the 2014 International Liver Congress(TM)

PR Newswire April 11, 2014

Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing Protease Inhibitor ABT-450 to be Presented at the European Association for the Study of the Liver (EASL) Meeting

Business Wire March 24, 2014

AbbVie to Present Detailed Results from Phase III Studies in Patients with Chronic Hepatitis C at the 2014 International Liver Congress(TM)

PR Newswire March 24, 2014

Enanta Pharmaceuticals Announces New Data Presented on Protease Inhibitor ABT-493 at the 21st Conference on Retroviruses and Opportunistic Infections (CROI)

Business Wire March 4, 2014

PEARL-III Study Results in Patients with Chronic Hepatitis C Presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI)

Business Wire March 3, 2014

AbbVie to Present Late-breaker PEARL-III Study in Patients with Chronic Hepatitis C at the 21st Conference on Retroviruses and Opportunistic Infections

PR Newswire March 3, 2014

Enanta Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference

Business Wire February 21, 2014

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2013

Business Wire February 13, 2014

Enanta Pharmaceuticals Announces the Appointment of George S. Golumbeski, Ph.D. to Board of Directors

Business Wire February 11, 2014

Enanta Pharmaceuticals to Present at the 2014 Leerink Global Healthcare Conference Presentation to be Webcast on February 13, 2014 at 2:15 P.M. ET

Business Wire February 6, 2014

Enanta Pharmaceuticals Announces the Appointment of Timothy D. Ocain, Ph.D. as Senior Vice President, New Product Strategy and Development

Business Wire February 3, 2014